The HELlenic Thoracic Society Initiative for CΟPD and CVD (HELICOPD)

Hellenic Thoracic Society

Status: Enrolling

Conditions: Cardiovascular Diseases (CVD); Chronic Obstructive Pulmonary Disease (COPD)

Study type: Observational

Funder types: Other

Identifiers

NCT06595784

HTS001

Details and patient eligibility

About

COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.

Enrollment: 900 estimated patients

Sex: All

Ages: 35 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Patients should cumulatively meet the following three (3) criteria to be enrolled in the study:

1. To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease)
2. Adults aged >35 years at the time of inclusion in the study,
3. With signed informed consent for their participation in the study. Exclusion criteria Patients with the below limitations are not eligible to participate in the study

Patients:

1. Without at least one cardiovascular comorbidity,
2. With history of lung cancer
3. With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy)
4. With any thoracic or abdominal surgery planned during study follow-up period
5. With participation in any COPD-related interventional study at study entry or during study duration.
6. Without signed informed consent for their participation in the study.

Trial design

900 participants in 1 patient group

COPD patients with cardiovascular comorbidities